Home
About
- Our Team
Technology
- Science
Pipeline
Partnerships
News & Updates
- Newsroom
- Events
Careers
Contact

Select Page

VANCE: First in Human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine

News & Updates

HELLO WORLD

ILLUSTRATOR

WRITER

WEB-DESIGNER

VANCE: First in Human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine

Jun 5, 2018

View/Download ASCO 2018 Poster

Search for:

Recent Posts

Vacancy: Director of Quality
Clinical trial data shows Oxford University’s COVID-19 vaccine produces strong immune response
Vacancy: Clinical Programme Lead
First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients
Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate

Vaccitech Limited

The Schrödinger Building
Heatley Road
The Oxford Science Park
Oxford
OX4 4GE

T: +44 (0)1865 818808

Home
About
Sitemap
Privacy Policy
Privacy Notice
Careers
Contact

Vaccitech is a T cell immunotherapy company developing products to treat and prevent infectious disease and cancer

Twitter
LinkedIn

© Vaccitech 2019 All rights reserved. Website by Brand Cooke